IA
KPTI icon

IFP Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

IFP Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-377
Closed -$52K – 2923
2018
Q4 		$52K Buy
377
+250
+197% +$42.2K ﹤0.01% 1593
2018
Q3 		$32K Buy
127
+7
+6% +$1.94K ﹤0.01% 2165
2018
Q2 		$31K Buy
120
+110
+1,100% +$27.2K ﹤0.01% 2205
2018
Q1 		$1K Hold
10
– – ﹤0.01% 3640
2017
Q4 		$1K Hold
10
– – ﹤0.01% 3691
2017
Q3 		$2K Hold
10
– – ﹤0.01% 3751
2017
Q2 		$1K Hold
10
– – ﹤0.01% 3900
2017
Q1 		$2K Hold
10
– – ﹤0.01% 3657
2016
Q4 		$1K Hold
10
– – ﹤0.01% 3796
2016
Q3 		$1K Sell
10
-33
-77% -$3.97K ﹤0.01% 3739
2016
Q2 		$4K Buy
+43
New +$5.59K ﹤0.01% 3250
2016
Q1 		– Sell
-33
Closed -$7K – 2920
2015
Q4 		$7K Buy
+33
New +$7.14K ﹤0.01% 2768

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

IFP Advisors's KPTI Position: Q1 2019 in Review

IFP Advisors sold out of Karyopharm Therapeutics (KPTI) in Q1 2019, closing a stake of 377 shares — an estimated $52K sold.

IFP Advisors first reported a position in KPTI in Q4 2015 and held it in 12 quarters. The position peaked at $52K in Q4 2018. 108 funds tracked by Wall St. Rank hold KPTI as of Q1 2019.

  • IFP Advisors reported no remaining Karyopharm Therapeutics position as of Q1 2019 after selling out during the quarter.
  • IFP Advisors sold 377 Karyopharm Therapeutics shares in Q1 2019, an estimated $52K.
  • IFP Advisors first reported a position in Karyopharm Therapeutics in Q4 2015 and held it in 12 quarters.
  • IFP Advisors's Karyopharm Therapeutics position peaked at $52K in Q4 2018.
  • 108 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2019.

Based on IFP Advisors's 13F filing for Q1 2019, filed 15 May 2019.